Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program

Reuters11-06

Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program

Dynavax Technologies Corporation reported third quarter 2025 financial results, with HEPLISAV-B quarterly net product revenue at $90.0 million, a 13% year-over-year increase. The company reiterated its full year 2025 HEPLISAV-B net product revenue guidance of $315.0 to $325.0 million. Adjusted EBITDA for the full year 2025 is expected to be at least $80.0 million, up from previous guidance of at least $75.0 million. The Board of Directors authorized a new $100.0 million share repurchase program. Dynavax also announced an exclusive license agreement for Vaxart's oral COVID-19 vaccine program, including a $25.0 million upfront license fee, a $5.0 million equity investment, and potential future milestone and royalty payments. Positive topline Phase 1/2 shingles vaccine trial data was presented during the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049515), on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581709443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581709443","market":"nz","top_or_hot":-1,"title":"Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dynavax Technologies Corporation reported third quarter 2025 financial results, with HEPLISAV-B quarterly net product revenue at $90.0 million, a 13% year-over-year increase. The company reiterated its full year 2025 HEPLISAV-B net product revenue guidance of $315.0 to $325.0 million. Adjusted EBITDA for the full year 2025 is expected to be at least $80.0 million, up from previous guidance of at least $75.0 million. The Board of Directors authorized a new $100.0 million share repurchase program. Dynavax also announced an exclusive license agreement for Vaxart's oral COVID-19 vaccine program, including a $25.0 million upfront license fee, a $5.0 million equity investment, and potential future milestone and royalty payments. Positive topline Phase 1/2 shingles vaccine trial data was presented during the period.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049515), on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dynavax Technologies Corporation reported third quarter 2025 financial results, with HEPLISAV-B quarterly net product revenue at $90.0 million, a 13% year-over-year increase. The company reiterated its full year 2025 HEPLISAV-B net product revenue guidance of $315.0 to $325.0 million. Adjusted EBITDA for the full year 2025 is expected to be at least $80.0 million, up from previous guidance of at least $75.0 million. The Board of Directors authorized a new $100.0 million share repurchase program. Dynavax also announced an exclusive license agreement for Vaxart's oral COVID-19 vaccine program, including a $25.0 million upfront license fee, a $5.0 million equity investment, and potential future milestone and royalty payments. Positive topline Phase 1/2 shingles vaccine trial data was presented during the period.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049515), on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLbFjbFD:1","article_id":"2581709443","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581709443","pubTimestamp":1762376640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dynavax Technologies Corporation reported third quarter 2025 financial results, with HEPLISAV-B quarterly net product revenue at $90.0 million, a 13% year-over-year increase. The company reiterated its full year 2025 HEPLISAV-B net product revenue guidance of $315.0 to $325.0 million. Adjusted EBITDA for the full year 2025 is expected to be at least $80.0 million, up from previous guidance of at least $75.0 million. The Board of Directors authorized a new $100.0 million share repurchase program. Dynavax also announced an exclusive license agreement for Vaxart's oral COVID-19 vaccine program, including a $25.0 million upfront license fee, a $5.0 million equity investment, and potential future milestone and royalty payments. Positive topline Phase 1/2 shingles vaccine trial data was presented during the period.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DVAX":"德纳维制药","BK4568":"美国抗疫概念","VXRT":"Vaxart, Inc."},"translate_title":"Dynavax报告第三季度HEPLISAV-B产品净收入为9000万美元，并宣布1亿美元的股票回购计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXRT":0.9,"DVAX":0.9},"content_text":"Dynavax reports Q3 HEPLISAV-B net product revenue of $90 million and announces $100 million share repurchase program\n    \n\n        Dynavax Technologies Corporation reported third quarter 2025 financial results, with HEPLISAV-B quarterly net product revenue at $90.0 million, a 13% year-over-year increase. The company reiterated its full year 2025 HEPLISAV-B net product revenue guidance of $315.0 to $325.0 million. Adjusted EBITDA for the full year 2025 is expected to be at least $80.0 million, up from previous guidance of at least $75.0 million. The Board of Directors authorized a new $100.0 million share repurchase program. Dynavax also announced an exclusive license agreement for Vaxart's oral COVID-19 vaccine program, including a $25.0 million upfront license fee, a $5.0 million equity investment, and potential future milestone and royalty payments. Positive topline Phase 1/2 shingles vaccine trial data was presented during the period.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dynavax Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-049515), on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581709443","isCrawlerRequest":true}